Immunisation Community of Practice

Share Immunisation Community of Practice on Facebook Share Immunisation Community of Practice on Twitter Share Immunisation Community of Practice on Linkedin Email Immunisation Community of Practice link

Welcome to the Immunisation Community of Practice. A community of practice (CoP) is a group of people with a shared passion who come together and learn how to do better. The PHNs Immunisation CoP is your opportunity to get answers, share ideas and build your professional network regarding immunisation.

The PHN Immunisation CoP aims to reduce the incidence of vaccine preventable diseases in the community by providing appropriate and timely information about vaccine preventable diseases and the Immunise Australia Program to immunisation providers and the community and promote the delivery of the National Immunisation Program (NIP).

Immunisation is a simple, safe and effective way of protecting people against harmful diseases that can cause serious health problems in the community. Immunisation not only protects individuals from life-threatening diseases, but also dramatically reduces transmission in the community. The more people who are vaccinated, the fewer opportunities a disease has to spread.

Some of the benefits of joining this Community are:

  • 24/7 access to filed Immunisation resources,
  • keep current with Immunisation updates,
  • brainstorm about Immunisation,
  • and network with colleagues passionate about Immunisation.

Welcome to the Immunisation Community of Practice. A community of practice (CoP) is a group of people with a shared passion who come together and learn how to do better. The PHNs Immunisation CoP is your opportunity to get answers, share ideas and build your professional network regarding immunisation.

The PHN Immunisation CoP aims to reduce the incidence of vaccine preventable diseases in the community by providing appropriate and timely information about vaccine preventable diseases and the Immunise Australia Program to immunisation providers and the community and promote the delivery of the National Immunisation Program (NIP).

Immunisation is a simple, safe and effective way of protecting people against harmful diseases that can cause serious health problems in the community. Immunisation not only protects individuals from life-threatening diseases, but also dramatically reduces transmission in the community. The more people who are vaccinated, the fewer opportunities a disease has to spread.

Some of the benefits of joining this Community are:

  • 24/7 access to filed Immunisation resources,
  • keep current with Immunisation updates,
  • brainstorm about Immunisation,
  • and network with colleagues passionate about Immunisation.
  • Updated vaccination and immunisation information

    Share Updated vaccination and immunisation information on Facebook Share Updated vaccination and immunisation information on Twitter Share Updated vaccination and immunisation information on Linkedin Email Updated vaccination and immunisation information link
    supporting image

    Updated FAQs for practitioners about vaccination and immunisation have been published on the Ahpra website.

    This follows Ahpra and the National Boards recently consulting with key stakeholders about what information would be helpful for registered health practitioners about vaccination and immunisation, taking into account public health advice and the high rates of vaccination against COVID-19 in Australia.

    The NMBA’s Position statement on nurses and midwives and vaccination will also be reviewed in line with current advice.

    The updated information about vaccination and immunisation draws from the National Boards’ regulatory tools, including:

  • Supplies of the Shingrix vaccine

    Share Supplies of the Shingrix vaccine on Facebook Share Supplies of the Shingrix vaccine on Twitter Share Supplies of the Shingrix vaccine on Linkedin Email Supplies of the Shingrix vaccine link

    The Australian Government has responded to unprecedented demand for the Shingrix vaccine, with over 487,000 doses administered within the initial three months of the program. As concerns arise over accessibility due to the surge in demand, officials assure the public that efforts are underway to ensure timely access for eligible Australians. With approximately half a million doses currently available nationwide and an additional 100,000 doses set for distribution in the coming fortnight, collaboration between federal, state, and territory governments, along with vaccine supplier GSK, aims to manage distribution equitably.

    The recent transition from Zostavax to Shingrix under the National Immunisation Program has necessitated adjustments, but health authorities stress that vaccination remains a crucial preventive measure against shingles. Eligible individuals, including those over 65, First Nations people over 50, and immunocompromised individuals, are encouraged to engage with their local healthcare providers for scheduling.

    More information is available on the Department of Health and Aged Care website.

  • AIR043A – Vaccine Details report

    Share AIR043A – Vaccine Details report on Facebook Share AIR043A – Vaccine Details report on Twitter Share AIR043A – Vaccine Details report on Linkedin Email AIR043A – Vaccine Details report link

    The new AIR043A – Vaccine Details report is available for vaccination providers through the AIR site. Vaccination providers can use this report to extract and reconcile vaccination information that they have previously reported to the AIR. The report contains information about the individual they have vaccinated and the relevant vaccine details (such as vaccine brand, vaccine type and route of administration).

    Pharmacies participating in the National Immunisation Program Vaccinations in Pharmacies (NIPVIP) Program may find this report useful for reconciling vaccinations provided when lodging claims for payment with the Pharmacy Programs Administrator. Further information about the AIR043A report is available on the Services Australia website.

  • March 2024 - new mandatory AIR reporting fields

    Share March 2024 - new mandatory AIR reporting fields on Facebook Share March 2024 - new mandatory AIR reporting fields on Twitter Share March 2024 - new mandatory AIR reporting fields on Linkedin Email March 2024 - new mandatory AIR reporting fields link

    From 1 March 2024, the Australian Immunisation Register (AIR) will have new mandatory reporting requirements. This will improve the data currently held.

    1. Vaccine Type

    Under the ‘vaccine type’ field, providers will be able to choose from 4 vaccine types:

    • Antenatal
    • NIP/Commonwealth
    • Private, or
    • State Program.

    Only one option can be selected under the ‘vaccine type’ field.

    The Antenatal option should be selected when the person presenting is pregnant at the time the vaccine is administered, regardless of whether the vaccine is funded privately, under the NIP or a state and territory program. COVID-19 vaccines should be reported as NIP/Commonwealth.

    2. Route of administration

    The ‘route of administration’ field will only be mandatory for Japanese encephalitis vaccines. Under the ‘route of administration’ field, providers will be able to choose from: Oral, Subcutaneous, Intradermal, or Intramuscular.

    Bp Premier

    The AIR mandatory changes were included in the current version of Bp Premier, Orchid SP1 Revision 1. Upgrade now to minimise the risk of implications to your practice and patients.

    MedicalDirector Clinical

    Availability of these reporting fields in MedicalDirector software will be reflected in Clinical version 4.3, which is available from 14 February 2024.



  • Opportunistic vaccination over the holiday period

    Share Opportunistic vaccination over the holiday period on Facebook Share Opportunistic vaccination over the holiday period on Twitter Share Opportunistic vaccination over the holiday period on Linkedin Email Opportunistic vaccination over the holiday period link

    Sites are encouraged to utilise all opportunities to vaccinate eligible patients – if a patient is eligible and requires a COVID-19 vaccine, do not delay, open a vial, and vaccinate them.

    Wastage of vaccine is an inevitable part of the COVID-19 program and there are no penalties for sites should wastage occur as we transition to a more opportunistic model of vaccination.

    Vaccine wastage is required to be recorded via weekly stock management reports.

    Excess COVID-19 vaccines?

    Practices with an oversupply of COVID-19 vaccine stock on hand are encouraged to contact HNECCPHN via email at vaccine@thephn.com.au to help facilitate transfer to practices to who require additional supply. Include details on vaccine brand, excess quantity and defrost expiry date.

  • 2024 Influenza Vaccines

    Share 2024 Influenza Vaccines on Facebook Share 2024 Influenza Vaccines on Twitter Share 2024 Influenza Vaccines on Linkedin Email 2024 Influenza Vaccines link

    The Australian Influenza Vaccine Committee (AIVC) has recommended the composition of the influenza vaccines for Australia in 2024 following review and evaluation of epidemiology, antigenic and genetic data of recent influenza viruses circulating in Australia and the southern hemisphere.

    Further information is available on the TGA website.

    Egg-based quadrivalent influenza vaccines AIVC recommendations:

    • an A/Victoria/4897/2022 (H1N1)pdm09-like virus; NEW
    • an A/Thailand/8/2022 (H3N2)-like virus; NEW
    • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
    • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

    Cell- or recombinant-based quadrivalent influenza vaccines AIVC recommendations:

    • an A/Wisconsin/67/2022 (H1N1)pdm09-like virus; NEW
    • an A/Massachusetts/18/2022 (H3N2)-like virus; NEW
    • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
    • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

    Resources on the 2024 influenza vaccination will be available ahead of the influenza vaccination program on the NSW Health website. Advice on when and how to order 2024 NIP influenza vaccines will be circulated in February 2024.

    The current formulations of influenza vaccine that are available to order from the State Vaccine Centre (SVC) are 2023 influenza vaccines.

    Please note the following expiration dates for 2023 influenza vaccines:

    • Vaxigrip Tetra: Expired on 31/12/2023 – DISCARD.
    • Fluarix Tetra: Expiring 29/02/2024 – monitor expiration date.
    • Afluria Quad: Expiring 29/02/2024 – monitor expiration date.
    • Fluad Quad: Expiring between 15/02/2024 and 17/02/2024 – monitor expiration date.


  • Novavax vaccine supply

    Share Novavax vaccine supply on Facebook Share Novavax vaccine supply on Twitter Share Novavax vaccine supply on Linkedin Email Novavax vaccine supply link

    Novavax ancestral formulation is no longer available to order from CVAS and current supply is close to expiry with last doses expiring Wednesday 31 January 2024.

    Providers are encouraged to recall any patients who are unable to have mRNA vaccines and have not received their recommended COVID-19 vaccinations before 31 January 2024 to receive a Novavax vaccine.

    A new Novavax XBB.1.5 formulation (Nuvaxovid) is currently under regulatory review and is expected to be available in time for the 2024 autumn respiratory season.

  • NCIRS study confirms decline in childhood vaccination coverage throughout COVID-19 pandemic

    Share NCIRS study confirms decline in childhood vaccination coverage throughout COVID-19 pandemic on Facebook Share NCIRS study confirms decline in childhood vaccination coverage throughout COVID-19 pandemic on Twitter Share NCIRS study confirms decline in childhood vaccination coverage throughout COVID-19 pandemic on Linkedin Email NCIRS study confirms decline in childhood vaccination coverage throughout COVID-19 pandemic link
    supporting image

    A new National Centre for Immunisation Research and Surveillance (NCIRS) report has uncovered a concerning downward trend in fully vaccinated coverage among Australian children since the onset of the COVID-19 pandemic.

    The Annual Immunisation Coverage Report 2022 is the first study of its kind to thoroughly examine the continuing effects of the COVID-19 pandemic on vaccination coverage in children, adolescents and adults across Australia.

    Fully vaccinated coverage in children was measured at three standard age assessment milestones – 12 months (for vaccines due at 6 months), 24 months (for vaccines due at 6, 12 and 18 months) and 60 months (for vaccines due at 4 years).

    Between 2021 and 2022, fully vaccinated coverage in children overall decreased:

    • from 94.2% to 93.3% at 12 months
    • from 92.1% to 91.0% at 24 months
    • from 94.0% to 93.4% at 60 months.

    Declines in fully vaccinated coverage in Aboriginal and Torres Strait Islander children were greater than in children overall – specifically:

    • from 91.6% to 90.0% at 12 months
    • from 90.1% to 87.9% at 24 months
    • from 96.3% to 95.1% at 60 months.

    These larger decreases in coverage among Aboriginal and Torres Strait Islander children – particularly those in remote areas – highlight the differential impacts of the COVID-19 pandemic and the need to improve the timeliness of routine and catch-up vaccinations.

    Improving on-time and catch-up vaccinations is a key pillar of the national goal to meet and exceed Australia’s immunisation coverage target of 95%.

    Although vaccination coverage in Australia is relatively high by global standards, childhood immunisation rates have continued to decline in the first half of 2023, underscoring the need for enhanced strategies to increase uptake and protect more children from vaccine preventable diseases.

    The full and summary versions of this report, as well as the accompanying NCIRS media release, can be accessed via the links below:

    Media release

    Annual Immunisation Coverage Report 2022 – Summary

    Annual Immunisation Coverage Report 2022

  • Ordering vaccines

    Share Ordering vaccines on Facebook Share Ordering vaccines on Twitter Share Ordering vaccines on Linkedin Email Ordering vaccines link

    Please place all orders on the the NSW State Vaccine Centre online web page

    Orders must be made online. Orders that are sent by Email or fax will no longer be accepted.

  • State Vaccine Centre Christmas closure

    Share State Vaccine Centre Christmas closure on Facebook Share State Vaccine Centre Christmas closure on Twitter Share State Vaccine Centre Christmas closure on Linkedin Email State Vaccine Centre Christmas closure link

    The State Vaccine Centre will be accepting vaccine orders until midday Tuesday 19th December to be dispatched Wednesday 20th December. Routine deliveries will recommence on Tuesday 2nd January 2024.

    Please do not order excessive stock over this period to avoid vaccine wastages in the event of unexpected power outages.

Page last updated: 07 Jun 2024, 02:19 PM